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Two polycythemic subjects from a family with multiple polycythemic subjects were evaluated. Estimation of 
oxygen affinity of Hb from venous blood gas parameters (P50) revealed low P50 suggesting a high affinity Hb 
variant. Further work up, which included beta globin gene sequencing, revealed a novel mutation changing a 
codon to the previously reported high affinity Hb - Hb Johnstown (beta109 Val->Leu). Polycythemic subjects 
with high affinity Hb variant are asymptomatic with normal life expectancy. Their differentiation from 
polycythemia vera (PV) is crucial to avoid therapy which is otherwise reserved for PV patients. We provide an 
electronic version (in Microsoft excel program) of a previously reported mathematical formula for rapid 
calculation of P50 from venous blood gases. Estimation of P50 is an essential initial step in the evaluation of a 
subject with personal and family history of polycythemia. 
Key words: High affinity Hb, Polycythemia, Estimation of P50 
1.  Background  
Polycythemia means many cells in the blood. 
Polycythemia is clinically defined as elevated red 
blood cell mass ( hemoglobin > 18.5 g/dL in men, 16.5 
g/dL in women or other evidence of increased red cell 
volume or hemoglobin or hematocrit greater than 99th 
percentile of method-specific reference range for age, 
sex, altitude of residence or hemoglobin greater than 
17 g/dL in men, 15 g/dL in women if associated with a 
documented and sustained increase of at least 2 g/dL 
from an individual's baseline value that can not be 
attributed to correction of iron deficiency, or elevated 
red cell mass greater than 25% above mean normal 
predicted value [1].  
Polycythemia can be further classified as primary 
polycythemia, secondary polycythemia, or 
polycythemia due to abnormal hypoxia sensing.  
Primary polycythemias are caused by intrinsic 
defects in the erythroid precursors that result in hyper 
responsiveness to normal level of serum 
erythropoietin (Epo). Secondary polycythemias are 
driven by the factors (predominantly Epo but also 
insulin growth factor 1 and cobalt) extrinsic to the 
erythroid progenitor cells. Generally, in secondary 
polycythemia, the increased red cell mass represents a 
physiologic response to tissue hypoxia or abnormally 
increased level of serum Epo [2].  
Polycythemias due to abnormal hypoxia sensing 
include Chuvash polycythemia, polycythemias 
associated with von Hippel-Lindau mutations other 
than the Chuvash polycythemia mutation, and 
polycythemia due to proline hydroxylase mutation [3, 
4]. Acquired conditions that lead to increased Epo 
production, such as chronic hypoxia and a variety of 
tumors, are the most common causes of secondary 
polycythemias.  
Secondary congenital polycythemia results from 
inherited conditions that lead to increased Epo levels. 
These include hemoglobin variants with high affinity 
for oxygen, congenitally low erythrocyte 2, 3 
biphosphoglycerate levels, and inherited 
methemoglobinemias. All these conditions are 
characterized by a left shift in Hb dissociation curve 
which in turn leads to tissue hypoxia and a 
physiologically appropriate increase in Epo levels. 
Congenital cyanotic heart or lung disorders, which 
lead to tissue hypoxia and increased Epo level are also 
examples of secondary congenital polycythemias but 
these are characterized by a normal Hb dissociation 
curve.  
2.  Methods 
Two subjects (mother and daughter), from a 
family with multiple subjects with polycythemia, were Int. J. Med. Sci. 2007, 4 
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available for evaluation:  
Subject 1(mother): She is a 59 year old Caucasian 
woman who presented with lifelong history of 
polycythemia. Her medical history was remarkable for 
1 )  m u l t i f o c a l  d u c t a l  c a r c i n o m a  i n  s i t u  ( D C I S )  o f  t h e  
breast in 2002, treated with simple mastectomy and 2) 
colonic diverticula and internal hemorrhoids since 
2005. Family history was remarkable for presence of 
lifelong history of polycythemia in her mother and two 
daughters. Physical examination was normal (no 
hepatosplenomegaly). Laboratory parameters revealed 
high Hb (16 gm%) , high hematocrit (48%), normal 
MCV, normal platelet and white blood cell counts, 
normal arterial oxygen saturation, and normal liver 
function tests.  
Subject 2 (daughter): She is a 30 year old Caucasian 
woman who presented for further evaluation of 
lifelong history of polycythemia. She had mild fatigue 
but no other symptoms. Past medical history was 
unremarkable. Family history was significant for 
lifelong history of polycythemia in her mother, 
maternal grandmother and her younger sister. 
Physical examination was unremarkable. Laboratory 
parameters were remarkable for elevated hemoglobin 
(17.2 gm%) and hematocrit (51.4%) but normal MCV, 
normal platelets and white blood cell counts, normal 
arterial oxygen saturation, and normal liver function 
tests.  
Both subjects underwent following laboratory 
tests: Serum Epo levels were normal in both subjects 
(15 mIU/ml and 19 mIU/ml respectively, normal 
range 4.1 - 19.5 mIU/ml). Venous blood gas 
parameters were obtained which included partial 
pressure of oxygen (venous pO2), venous pH and 
venous oxygen saturation. Calculation of affinity of Hb 
for oxygen (P50) was done using the mathematical 
formula as described [5]. Routine Hb electrophoreses, 
high performance liquid chromatography (HPLC) [6, 
7], isoelectric focusing (IEF) in polyacrylamide gel, 
globin chain analysis [8] and peptide mapping [9] were 
performed. This was followed by beta globin gene 
sequencing which was performed by ABI3730 
96-capillary sequencer at the DNA Sequencing Core 
Facility at the University of Utah School of Medicine 
(primers and conditions available upon request).  
3.  Results and Discussion 
The P50 was found to be low at 18 mm Hg 
(normal range 22.6 to 29.4) suggesting increased 
affinity of Hb for oxygen. Routine Hb electrophoresis 
and HPLC failed to detect mutant hemoglobin. IEF 
showed a band anodal to Hb A and globin chain 
analysis by HPLC revealed an unidentified beta globin 
variant in both subjects (Figure 1). Peptide mapping 
showed an extra peak at 26.9 min but showed no 
decrease in any peaks suggesting a mutation 
somewhere in the core (Figure 2). Beta globin gene 
sequencing revealed a novel mutation (GTG->TTG ) of 
codon 109 of exon 3 of beta globin gene. This mutation 
leads to a previously reported high affinity Hb variant 
known as Hb Johnstown (beta109 Val->Leu) [10-12]; 
however, this nucleotide change is novel and 
previously unreported; and it leads to a previously 
described amino acid substitution that was however, 
caused by a different nucleotide missense mutation.  
Hb Johnstown (beta109 (G11) Val->Leu) is a high 
oxygen affinity Hb variant and there are three reports 
in the literature. It was first reported by Jones and 
colleagues in Oregon, in 1990, in a healthy 
asymptomatic subject with mild erythrocytosis and 
left-shifted hemoglobin-O2 dissociation curve[10]. As 
with many other Hb variants, Hb Johnstown is silent 
on standard hemoglobin electrophoretic analyses, and 
was identified and isolated by reverse-phase HPLC of 
individual globin chains. Structural analysis revealed 
the substitution beta 109 (G11) Val ->Leu [10]. In 2000, 
the underlying beta globin mutation [beta-globin 
codon 109 (GTG ->CTG )] was first reported by Ropero 
and colleagues, in two unrelated families (total four 
subjects) of Basque extraction in Spain [11]. In one of 
these families, Hb Johnstown mutation was present in 
double heterozygosity with another beta 0 thalassemia 
mutation IVS-1-nt1 (G->A). In 2004, Feliu-Torres and 
colleagues reported Hb Johnstown [beta-globin codon 
109 (GTG ->CTG )] in an eight year old girl, who had 
been referred for evaluation of erythrocytosis, in 
double heterozygosity with another beta globin 
mutation [IVS-I-1(G->A)]. Her asymptomatic mother 
was found to be heterozygous for Hb Johnstown 
mutation [12]. However, these reports described a 
causative G to C mutation that is different that 
mutation we describe in our subject with Hb 
Johnstown, namely G to T, both encoding the same 
amino acid; i.e. leucine and present in subjects not 
known to be of Spanish/Basque extraction. 
Oxygenation and deoxygenation of hemoglobin 
occur at the heme iron. The sigmoid shape of 
Hb-oxygen dissociation curve is indicative of 
cooperative interaction between heme and oxygen. 
Oxygen affinity and Hb-oxygen dissociation is affected 
by blood pH, 2, 3- biphosphoglycerate (2, 3 BPG) level 
in the red cell and temperature, and globin structure 
[13].  
Affinity of Hb with oxygen is expressed as the 
P50, which is the partial pressure of oxygen in blood at 
which 50% of the Hb is saturated with oxygen. The 
venous P50 can be measured directly using a 
cooximeter which is no longer easily available in 
routine and even reference laboratories. Lichtman and 
colleagues have reported a mathematical formula 
which can be used to calculate P50 reliably [5]. 
Calculating P50 using this formula requires the 
following venous gas parameters: partial pressure of 
oxygen (venous pO2), venous pH and venous oxygen 
saturation, and uses anti-log mathematical function 
that many clinicians find difficult to use for calculation 
[5]. The P50 of a healthy person with normal Hb is 26 ± 
1.3 mm Hg. The 99% confidence interval for individual 
observations has been reported to be 22.6 to 29.4 mm 
Hg. An abnormally low P50 reflects an increased 
affinity of hemoglobin for oxygen and vice versa. 
Elevations and reductions in 2, 3- BPG level in the Int. J. Med. Sci. 2007, 4 
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erythrocyte will also lead to corresponding changes in 
P50 values; however, in only reported subjects this 
decrease was limited to a P50 value between 20 and 35 
mm Hg. There should be high suspicion for the 
presence of a high affinity Hb variant if P50 value is 
<20 mm Hg [5]. 
During oxygenation and deoxygenation, there is 
considerable movement along the interface of alpha 1 
and beta 2 chains of the Hb tetramer. Several 
hemoglobin variants have substitutions affecting this 
interface. All these substitutions can affect the 
cooperative nature of oxygen binding with heme, and 
in turn, can change the affinity of Hb for oxygen. The 
majority of mutations affecting oxygen affinity result 
in high affinity Hb variants which result in leftward 
shift of the dissociation curve and relative tissue 
hypoxia [14]. There are 90 high affinity Hb variants, 
listed on the globin server, known to be associated 
with high affinity for oxygen 
(http://globin.bx.psu.edu/hbvar/menu.html 
accessed on May 04, 2007) [15]. All these Hb variants 
are inherited in an autosomal dominant manner. High 
affinity Hb variants release oxygen in the tissue 
relatively slowly and create relative tissue hypoxia. 
This leads to increased production of Epo from 
kidneys which results in increased red blood cell mass 
and polycythemia. At an elevated level of increased 
red blood cell mass (which depends upon the oxygen 
affinity of a given variant) adequate oxygenation of the 
tissue is reestablished and Epo production plateaus 
and at this new steady state serum Epo is often at 
normal level. This leads to stabilization of Hb level 




Figure 1. HPLC globin chain separation. Y axis denotes relative mass, X axis denotes the retention time in minutes. The unidentified 




Figure 2. HPLC peptide mapping. Y axis denotes relative mass, X axis denotes the retention time in minutes. An extra peak at 26.9 
min (X) was seen without decrease in any other peaks suggesting a mutation somewhere in the core. 
 
4.  Conclusion 
Family history of polycythemia in a subject with 
polycythemia should raise the suspicion for the 
presence of a high affinity Hb variant [14]. A low P50 
value (obtained from venous gas parameters) is 
supportive of high oxygen affinity Hb variant or 
decreased 2, 3 BPG level. In a polycythemic patient, 
establishing a correct diagnosis of a high affinity Hb 
variant is important as these patients have normal life 
expectancy and do not require phlebotomy. The 
therapies used for polycythemia vera such as 
phlebotomy and chemotherapy should not be used in 
patients who have polycythemia due to high affinity 
Hb variants. With this report, we are providing an 
electronic version (using Microsoft Excel program) of 
the mathematical formula [5], with which P50 can be 
c a l c u l a t e d  i n  f e w  s e c o n d s ,  p r o v i d e d  v e n o u s  g a s  
parameters are available, without necessity of more 
sophisticated calculations using antilog parameters. 
With increased ease and rapidity of calculation using 
our Excel program (Supplementary Material), we hope 
that use of P50 will increase, leading to improved 
detection of Hb variants in subjects with familial 
polycythemia. 
Supplementary Material 
Excel program [http://www.medsci.org/v04p0232s1.xls] 
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